دورية أكاديمية
Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
| العنوان: | Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer. |
|---|---|
| المؤلفون: | Stone RL; Johns Hopkins School of Medicine, 600 N Wolfe St, Phipps 281, Baltimore, MD 21287, USA., Cambron-Mellott MJ; Cerner Enviza, 51 Valley Stream Pkwy, Malvern, PA 19355, USA., Beusterien K; Cerner Enviza, 51 Valley Stream Pkwy, Malvern, PA 19355, USA., Maculaitis MC; Cerner Enviza, 51 Valley Stream Pkwy, Malvern, PA 19355, USA., Ritz S; Cerner Enviza, 51 Valley Stream Pkwy, Malvern, PA 19355, USA., Mulvihill E; Cerner Enviza, 51 Valley Stream Pkwy, Malvern, PA 19355, USA., Monberg M; Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA., Szamreta EA; Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA., Amin S; AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA., McLaurin K; AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA. |
| المصدر: | Future oncology (London, England) [Future Oncol] 2022 Feb; Vol. 18 (4), pp. 491-503. Date of Electronic Publication: 2021 Dec 08. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Future Medicine Ltd., c2005- |
| مواضيع طبية MeSH: | Carcinoma, Ovarian Epithelial/*drug therapy , Oncologists/*statistics & numerical data , Ovarian Neoplasms/*drug therapy , Patient Preference/*statistics & numerical data , Poly(ADP-ribose) Polymerase Inhibitors/*therapeutic use, Adult ; Aged ; Cost-Benefit Analysis ; Decision Making ; Drug-Related Side Effects and Adverse Reactions/therapy ; Female ; Humans ; Maintenance Chemotherapy ; Middle Aged ; Progression-Free Survival ; United States/epidemiology ; Young Adult |
| مستخلص: | Aim: To understand the preferences of US patients and oncologists for PARP inhibitors as second-line maintenance (2LM) for epithelial ovarian cancer. Methods: A discrete choice experiment was conducted to assess the preferences of treatment attributes. Results: The most valued attributes were risk of grade 3/4 adverse events (AEs; patients, n = 204) and progression-free survival (PFS; oncologists, n = 151). To accept a 37% increased risk of grade 3/4 AEs, PFS would need to increase by 27.9 months (patients) and 6.3 months (oncologists). The least valued attributes were dosing form/frequency (patients) and grade 3/4 anemia risk (oncologists). Conclusion: Patients' and oncologists' willingness to make benefit-risk trade-offs in the 2LM setting suggests that the PFS gains observed in selected studies of poly (ADP-ribose) polymerase inhibitors in BRCA-mutated disease are worth the toxicity risk. |
| معلومات مُعتمدة: | Merck Sharp & Dohme Corp. (MSD), a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; AstraZeneca |
| فهرسة مساهمة: | Keywords: PARP inhibitors; epithelial ovarian cancer; maintenance therapy; patient preferences; physician preferences Local Abstract: [plain-language-summary] Plain language summary Maintenance therapy is a treatment option intended to keep ovarian cancer from coming back or getting worse for as long as possible after responding to chemotherapy. PARP inhibitors are a new type of maintenance therapy for ovarian cancer. This study aimed to understand the patients' and physicians' preferences for the benefits and risks associated with different PARP inhibitors used as maintenance therapy for ovarian cancer. Participants were asked to compare various treatment options based on their different safety profiles, effectiveness and form of medication (e.g., three capsules by mouth once a day versus two tablets by mouth twice a day), and then choose the treatment they most preferred. Through this exercise, the treatment features that mattered most to patients and physicians were identified. The most important treatment feature for patients was decreasing the chance of experiencing a serious side effect that requires medical intervention or hospitalization. In contrast, physicians valued lengthening the time that a cancer remains stable and does not worsen. To accept a 37% higher chance of experiencing a side effect that requires medical intervention or hospitalization, patients expect their cancer to remain stable and not worsen for an additional 28 months. This was a large difference from the 6 months that the physicians would consider as acceptable. The least important treatment features for patients are the amount of pills required per dose, the form of the given medication (e.g., tablet vs capsule) and the schedule of taking the treatment. On the other hand, physicians were least concerned about lowering the risk of experiencing low blood counts that, requiring medical intervention. |
| المشرفين على المادة: | 0 (Poly(ADP-ribose) Polymerase Inhibitors) |
| تواريخ الأحداث: | Date Created: 20211208 Date Completed: 20220318 Latest Revision: 20220318 |
| رمز التحديث: | 20221213 |
| DOI: | 10.2217/fon-2021-0567 |
| PMID: | 34875854 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-8301 |
|---|---|
| DOI: | 10.2217/fon-2021-0567 |